The post-hoc analysis from the Diabetes Mellitus Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) 2 trial on extended long-term outcome disclosed that insulin based treatment might be associated with increased risk of nonfatal cardiac events.[25] Hall et al[26] reported that adding insulin after 1 oral glucose-lowering drug (OGLD), when compared with adding another OGLD, had poor macrovascular outcomes. This evidence concerns the gene INS and myocardial infarction.